Rhumbline Advisers Has $58.75 Million Holdings in Illumina, Inc. $ILMN

Rhumbline Advisers cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 618,663 shares of the life sciences company’s stock after selling 13,289 shares during the period. Rhumbline Advisers’ holdings in Illumina were worth $58,754,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ILMN. Envestnet Portfolio Solutions Inc. lifted its position in shares of Illumina by 0.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after acquiring an additional 99 shares in the last quarter. Versant Capital Management Inc raised its stake in Illumina by 8.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after purchasing an additional 111 shares during the period. Parkside Financial Bank & Trust lifted its holdings in shares of Illumina by 65.7% in the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares in the last quarter. Archer Investment Corp boosted its position in shares of Illumina by 12.9% in the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after buying an additional 123 shares during the period. Finally, Callan Family Office LLC boosted its position in shares of Illumina by 4.4% in the third quarter. Callan Family Office LLC now owns 2,939 shares of the life sciences company’s stock worth $279,000 after buying an additional 124 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 1.7%

NASDAQ:ILMN opened at $114.44 on Friday. The company has a market capitalization of $17.49 billion, a P/E ratio of 21.00, a P/E/G ratio of 2.23 and a beta of 1.45. The stock’s 50 day moving average price is $137.54 and its 200 day moving average price is $116.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. During the same period in the previous year, the firm posted $0.95 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ILMN shares. Guggenheim increased their price objective on Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research report on Monday, January 26th. Evercore set a $150.00 price objective on shares of Illumina in a research report on Friday, February 6th. Evercore ISI set a $150.00 price objective on shares of Illumina in a research note on Friday, February 6th. Finally, Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 31st. Six equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and an average price target of $129.17.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $136.09, for a total transaction of $43,957.07. Following the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.